314 related articles for article (PubMed ID: 33358151)
1. Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds.
Zoumpourlis P; Genovese G; Tannir NM; Msaouel P
Clin Genitourin Cancer; 2021 Apr; 19(2):103-116. PubMed ID: 33358151
[TBL] [Abstract][Full Text] [Related]
2. Advances in non-clear cell renal cell carcinoma management: From heterogeneous biology to treatment options.
Wilson NR; Acikgoz Y; Hasanov E
Int J Cancer; 2024 Mar; 154(6):947-961. PubMed ID: 37823185
[TBL] [Abstract][Full Text] [Related]
3. Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview.
Bergmann L; Weber S; Hartmann A; Ahrens M
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1273-1286. PubMed ID: 34291700
[No Abstract] [Full Text] [Related]
4. Advanced nccRCC: what therapeutic options in 2022?
Bigot C; Boudier P; Ladoire S; Barthélémy P
Bull Cancer; 2022 May; 109(2S):2S39-2S46. PubMed ID: 35760469
[TBL] [Abstract][Full Text] [Related]
5. The incidence, pathogenesis, and management of non-clear cell renal cell carcinoma.
Naik P; Dudipala H; Chen YW; Rose B; Bagrodia A; McKay RR
Ther Adv Urol; 2024; 16():17562872241232578. PubMed ID: 38434237
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.
Tannir NM; Plimack E; Ng C; Tamboli P; Bekele NB; Xiao L; Smith L; Lim Z; Pagliaro L; Araujo J; Aparicio A; Matin S; Wood CG; Jonasch E
Eur Urol; 2012 Dec; 62(6):1013-9. PubMed ID: 22771265
[TBL] [Abstract][Full Text] [Related]
7. Start of a New Era: Management of Non-Clear Cell Renal Cell Carcinoma in 2022.
Maughan BL
Curr Oncol Rep; 2022 Sep; 24(9):1201-1208. PubMed ID: 35438388
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis.
Chahoud J; Msaouel P; Campbell MT; Bathala T; Xiao L; Gao J; Zurita AJ; Shah AY; Jonasch E; Sharma P; Tannir NM
Oncologist; 2020 Mar; 25(3):252-258. PubMed ID: 32162795
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study.
Izumi K; Inoue M; Washino S; Shirotake S; Kagawa M; Takeshita H; Miura Y; Hyodo Y; Oyama M; Kawakami S; Miyagawa T; Saito K; Kageyama Y
Int J Urol; 2023 Sep; 30(9):714-721. PubMed ID: 36541136
[TBL] [Abstract][Full Text] [Related]
10. Renal Cell Carcinoma of Variant Histology: Biology and Therapies.
Msaouel P; Genovese G; Tannir NM
Hematol Oncol Clin North Am; 2023 Oct; 37(5):977-992. PubMed ID: 37244822
[TBL] [Abstract][Full Text] [Related]
11. Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature.
John A; Spain L; Hamid AA
Curr Oncol; 2023 Jan; 30(1):923-937. PubMed ID: 36661719
[TBL] [Abstract][Full Text] [Related]
12. Real World Data of Diagnosis, Survival, and Treatment Outcomes in Patients With Metastatic Non Clear Cell Renal Cell Carcinoma.
Izarn F; Allignet B; Gille R; Boyle H; Neidhardt EM; Négrier S; Fléchon A
Clin Genitourin Cancer; 2023 Apr; 21(2):e35-e43. PubMed ID: 36272959
[TBL] [Abstract][Full Text] [Related]
13. The role of immunotherapy treatment in non-clear cell renal cell carcinoma: An analysis of the literature.
Ventriglia J; Passarelli A; Pisano C; Cecere SC; Rossetti S; Feroce F; Forte M; Casartelli C; Tambaro R; Pignata S; Perversi F; Di Napoli M
Crit Rev Oncol Hematol; 2023 Aug; 188():104036. PubMed ID: 37263397
[TBL] [Abstract][Full Text] [Related]
14. Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?
Albiges L; Molinie V; Escudier B
Oncologist; 2012; 17(8):1051-62. PubMed ID: 22807514
[TBL] [Abstract][Full Text] [Related]
15. Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options.
Ahrens M; Scheich S; Hartmann A; Bergmann L;
Oncol Res Treat; 2019; 42(3):128-135. PubMed ID: 30799404
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapies and the treatment of non-clear cell renal cell carcinoma.
Bellmunt J; Dutcher J
Ann Oncol; 2013 Jul; 24(7):1730-1740. PubMed ID: 23625974
[TBL] [Abstract][Full Text] [Related]
17. Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial.
Barata PC; Chehrazi-Raffle A; Allman KD; Asnis-Alibozek A; Kasturi V; Pal SK
Oncologist; 2023 Oct; 28(10):894-900. PubMed ID: 37315114
[TBL] [Abstract][Full Text] [Related]
18. The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review.
Sneed GT; Lee S; Brown JN; Hammond JM
Clin Genitourin Cancer; 2019 Dec; 17(6):419-424. PubMed ID: 31585694
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma.
Osterman CK; Rose TL
Kidney Cancer; 2020; 4(1):15-27. PubMed ID: 34435168
[TBL] [Abstract][Full Text] [Related]
20. Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data.
Barthélémy P; Rioux-Leclercq N; Thibault C; Saldana C; Borchiellini D; Chevreau C; Desmoulins I; Gobert A; Hilgers W; Khalil A; Lemoine N; Schlürmann-Constans F; Négrier S
Cancer Treat Rev; 2021 Jun; 97():102191. PubMed ID: 34015728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
